News | July 23, 2024
Solara Active Pharma Sciences reports Q1 FY25 consolidated loss at Rs. 13.46 Cr
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
